Back to results
US 2016/0102074 A1Published application
Substituted amide compounds
AssigneePfizer Inc.
InventorsEtzer Darout, Kim F. McClure, David Piotrowski, Brian Raymer
Life of this patent
Estimating the term…
Abstract
The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.
Claims8
-18. (canceled)
The compound:
- ethyl (S)-1-{5-[4-(4-{(3-chloropyridin-2-yl)[(3R)-piperidin-3-yl]carbamoyl}-2-fluorophenyl)-1-methyl-1H-pyrazol-5-yl]-1H-tetrazol-1-yl}ethyl carbonate or a pharmaceutically acceptable salt thereof.
The compound
-40. (canceled)
The compound:
- ethyl (S)-1-{5-[4-(4-{(3-chloropyridin-2-yl)[(3R)-piperidin-3-yl]carbamoyl}-2-fluorophenyl)-1-methyl-1H-pyrazol-5-yl]-1H-tetrazol-1-yl}ethyl carbonate hydrochloride.
Dependencies are inferred from the claim text.